These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 26099669)
1. PET/Computed Tomography in the Diagnosis and Staging of Gastric Cancers. Malibari N; Hickeson M; Lisbona R PET Clin; 2015 Jul; 10(3):311-26. PubMed ID: 26099669 [TBL] [Abstract][Full Text] [Related]
2. Metabolic information on staging FDG-PET-CT as a prognostic tool in the evaluation of 97 patients with gastric cancer. Coupe NA; Karikios D; Chong S; Yap J; Ng W; Merrett N; Lin M Ann Nucl Med; 2014 Feb; 28(2):128-35. PubMed ID: 24297388 [TBL] [Abstract][Full Text] [Related]
3. Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT. Yun M; Lim JS; Noh SH; Hyung WJ; Cheong JH; Bong JK; Cho A; Lee JD J Nucl Med; 2005 Oct; 46(10):1582-8. PubMed ID: 16204706 [TBL] [Abstract][Full Text] [Related]
4. Diagnosis and evaluation of gastric cancer by positron emission tomography. Wu CX; Zhu ZH World J Gastroenterol; 2014 Apr; 20(16):4574-85. PubMed ID: 24782610 [TBL] [Abstract][Full Text] [Related]
6. Performance of (18)F-FDG PET/CT as a postoperative surveillance imaging modality for asymptomatic advanced gastric cancer patients. Lee DY; Lee CH; Seo MJ; Lee SH; Ryu JS; Lee JJ Ann Nucl Med; 2014 Oct; 28(8):789-95. PubMed ID: 24965850 [TBL] [Abstract][Full Text] [Related]
7. Spectrum of gastric malignancy on 18F-FDG PET/CT: a pictorial essay. Makis W; Ciarallo A; Hickeson M; Rush C; Derbekyan V; Novales-Diaz JA; Laufer J; Stern J; Lisbona R Clin Imaging; 2012; 36(5):432-46. PubMed ID: 22920343 [TBL] [Abstract][Full Text] [Related]
8. A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer. Smyth E; Schöder H; Strong VE; Capanu M; Kelsen DP; Coit DG; Shah MA Cancer; 2012 Nov; 118(22):5481-8. PubMed ID: 22549558 [TBL] [Abstract][Full Text] [Related]
9. FDG PET-CT for lymph node staging of bladder cancer: a prospective study of patients with extended pelvic lymphadenectomy. Jeong IG; Hong S; You D; Hong JH; Ahn H; Kim CS Ann Surg Oncol; 2015 Sep; 22(9):3150-6. PubMed ID: 25634779 [TBL] [Abstract][Full Text] [Related]
10. Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer. Laurens ST; Oyen WJ PET Clin; 2015 Jul; 10(3):345-60. PubMed ID: 26099671 [TBL] [Abstract][Full Text] [Related]
11. Comparison between 18F-FDG PET/MRI and MDCT for the assessment of preoperative staging and resectability of gastric cancer. Lee DH; Kim SH; Joo I; Hur BY; Han JK Eur J Radiol; 2016 Jun; 85(6):1085-91. PubMed ID: 27161056 [TBL] [Abstract][Full Text] [Related]
12. Usefulness of combined PET/CT to assess regional lymph node involvement in gastric cancer. Park K; Jang G; Baek S; Song H Tumori; 2014; 100(2):201-6. PubMed ID: 24852866 [TBL] [Abstract][Full Text] [Related]
13. PET and PET-CT in esophageal and gastric cancer. Wieder HA; Krause BJ; Herrmann K Methods Mol Biol; 2011; 727():59-76. PubMed ID: 21331929 [TBL] [Abstract][Full Text] [Related]
14. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Swinnen G; Maes A; Pottel H; Vanneste A; Billiet I; Lesage K; Werbrouck P Eur Urol; 2010 Apr; 57(4):641-7. PubMed ID: 19477579 [TBL] [Abstract][Full Text] [Related]
15. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence. Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206 [TBL] [Abstract][Full Text] [Related]
16. Contrast-enhanced [(18)F]fluorodeoxyglucose-positron emission tomography/computed tomography for staging and radiotherapy planning in patients with anal cancer. Bannas P; Weber C; Adam G; Frenzel T; Derlin T; Mester J; Klutmann S Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):445-51. PubMed ID: 20832181 [TBL] [Abstract][Full Text] [Related]
17. FDG PET/CT in the management of colorectal and anal cancers. Agarwal A; Marcus C; Xiao J; Nene P; Kachnic LA; Subramaniam RM AJR Am J Roentgenol; 2014 Nov; 203(5):1109-19. PubMed ID: 25341152 [TBL] [Abstract][Full Text] [Related]
18. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities. Salem SS; Shahin MA Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387 [TBL] [Abstract][Full Text] [Related]
19. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions? Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088 [TBL] [Abstract][Full Text] [Related]
20. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]